Bellus Health

Last updated: 13.02.2014

Bellus Health is a development-focused healthcare company concentrating on products that provide innovative health solutions and address critical unmet medical needs. The Company’s product pipeline and development strategy includes two pharmaceutical drug candidates and one commercial stage nutraceutical product.

The Company’s lead program is KIACTA, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA is partnered with global private equity firm Auven Therapeutics. AA amyloidosis affects approximately 35,000 to 50,000 individuals in the United States, Europe and Japan.

Bellus Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.

275 Armand-Frappier Blvd.




H7V 4A7

Tel.: (450) 680-4500

Fax: (450) 680-4501



We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here